Newsroom

Strive to Deliver Breakthroughs

  1. June 05, 2023

    Harbour BioMed Announces First Patient Dosed in Phase I Study of First-in-Class Anti-B7H7 (HHLA2) Antibody HBM1020

    HBM1020 is a first-in-class therapeutic monoclonal antibody against B7H7/HHLA2 entering clinical development globally. HBM1020 was generated from Harbour ...

    View more
  2. May 26, 2023

    Harbour BioMed Reports Results of Phase Ib Clinical Trial of Porustobart in Combination of Toripalimab in Patients with Hepatocellular Carcinoma at ASCO 2023

      Porustobart in combination of toripalimab showed promising anti-tumor activity Porustobart in combination of toripalimab showed acceptable safet...

    View more
  3. April 14, 2023

    Harbour BioMed Announces Results of Phase Ib Clinical Trial of Porustobart in Combination with Toripalimab in Advanced High-Grade Neuroendocrine Neoplasms at AACR Annual Meeting

    Porustobart in combination with toripalimab showed promising anti-tumor activity in advanced high-grade neuroendocrine neoplasms (NENs) The ORR and DCR we...

    View more
  4. April 10, 2023

    Harbour BioMed Reports Full Year 2022 Financial Results

    CAMBRIDGE, Mass., SUZHOU, China and ROTTERDAM, Netherlands, April 3, 2023 /PRNewswire/ -- Harbour BioMed ("HBM" or...

    View more
  5. March 06, 2023

    Harbour BioMed Announces Positive Topline Results from Phase III Trial of Batoclimab for Treatment of Generalized Myasthenia Gravis

    Cambridge, MA, Rotterdam, NL, Suzhou, CN – March 6, 2023   Harbour BioMed (the "Company”; HKEX: 02142), a global biopharmaceutical ...

    View more
  6. February 14, 2023

    Cullinan Oncology Licenses U.S. Rights to the First Clinical-Stage B7H4 x 4-1BB Bispecific Immune Activator from Harbour BioMed

    CAMBRIDGE, Mass., February 14, 2023   Cullinan Oncology, Inc. (Nasdaq: CGEM) and Harbour BioMed (HKEX: 02142) today announced that Cullinan Onc...

    View more
  7. February 07, 2023

    Harbour BioMed Announces IND Clearance for Novel G Protein-coupled Receptor HBM1022 Targeting CCR8 in the U.S.

    HBM1022 is a monoclonal antibody generated from Harbour BioMed’s integrated G protein-coupled receptor (GPCR) platform HBM1022 presented cynomolgus ...

    View more
  8. January 26, 2023

    HBM Alpha Therapeutics Raises Seed Round to Advance Next-Gen Therapies for Endocrine Disorders

    Cambridge, MA, January 26, 2023   HBM Alpha Therapeutics (HBMAT), Inc., an innovative biotechnology company incubated by Harbour BioMed (HKEX: 02142...

    View more
  9. January 19, 2023

    Harbour BioMed Announces IND Clearance for HBM1007 Targeting CD73 in the U.S.

    HBM1007 is a fully-human monoclonal antibody targeting CD73 HBM1007 is generated from Harbour Mice®  H2L2 platform With unique epitopes to...

    View more
  10. January 12, 2023

    Harbour BioMed Announces IND Clearance for First-in-Class Anti-B7H7 (HHLA2) Antibody by the U.S. FDA

    HBM1020 is the globally first-in-class fully human monoclonal antibody targeting B7H7. HBM1020 is also the globally first-ever monoclonal antibody targeti...

    View more